NCT06313996 2026-03-18A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 3 Withdrawn
NCT04607772 2025-10-03Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)Karyopharm Therapeutics IncPhase 1/2 Withdrawn